LMG Life Sciences has honored Fenwick among the top firms for its work with life sciences companies. Fenwick ranks among the leading firms in the U.S. for licensing and collaboration, patent prosecution, and patent strategy and management.
In addition, several Fenwick partners received recognition as leaders in the life sciences space. Corporate partners Michael Brown, Gordon Davidson, Robert Freedman, Stephen Graham and Effie Toshav were named Life Sciences Stars for financial and corporate work. Intellectual property partners Daniel Becker and Bob Hulse – along with IP litigation partners Adam Gahtan and Jeffrey Oelke – were also honored as Life Sciences Stars.
In its profile of the firm, LMG Life Sciences called out various strengths of the Fenwick team, noting firm partners as "highly creative," a “top-notch patent strategist in both small molecule drug and complex biologics," a "great listener," combining “expertise in software and technology with Fenwick's life sciences clientele,” and “well-versed in Hatch-Waxman disputes for branded drug makers.”
LMG Life Sciences also highlighted that Fenwick made news with the addition of a life sciences-focused, IP litigation group in the firm’s New York office.
Fenwick’s life sciences team serves companies pursuing diverse technologies including precision medicine, digital health, immuno-oncology, gene therapy, diagnostics, large- and small-molecule therapeutics and ag-biotech.
The group recently closed multiple initial public offerings for life sciences companies including Stoke Therapeutics’ $163 million IPO, Adaptive Biotechnologies’ $345 million IPO and Morphic Holding’s $103.5 million IPO. In addition, the firm handled significant life sciences M&A deals including Loxo Oncology’s $8 billion acquisition by Lilly, secured multiple litigation victories and helped cutting-edge companies develop their patent portfolios.
Fenwick’s full 2019 rankings are available on the LMG Life Sciences website.